Atlas Trials

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

Clinical trial NCT06343948 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06343948
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
HR+HER2- Breast Cancer
Start date
2024-04-24
Primary completion
2026-08-01
Enrollment
383

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.